JNJ Stock Recent News

FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.

Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build manufacturing facilities and research infrastructure in the United States.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds upon the Company's already elevated U.S. investment levels resulting from the passage of the 2017.

For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025. One of the most well-known dividend strategies is owning Dividend Aristocrats, of which the NOBL ETF tracks. In the 5 years since the COVID crash low, growth stocks have been the primary driver of the market, especially since the start of the AI boom beginning in late 2022.

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA ®  in all pooled endoscopic endpoints within a double-blinded registrational trial  TREMFYA® approval in Crohn's disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S. HORSHAM, Pa. , March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of TREMFYA® in mod

PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) for patients with lung cancer (NSCLC) to be presented at the 2025 European Lung Cancer Conference (“ELCC”).

Johnson & Johnson JNJ just hit a Golden Cross , a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum.

Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience RARITAN, N.J. , March 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.